Baird Medical Investment Holdings Ltd
Description
Baird Medical Investment Holdings Limited, together with its subsidiaries develops and sells microwave ablation medical devices for minimally invasive tumor treatment in China and the United States. The company's medical devices are used for treatment of benign and malignant tumors, including thyroid nodules, liver cancer, lung cancer, and breast lumps. Baird Medical Investment Holdings Limited was founded in 2012 and is headquartered in Guangzhou, China.
About
CEO
Ms. Haimei Wu
Employees
148
Instrument type
Common Stock
Sector
Healthcare
Industry
Medical Devices
MIC code
XNCM
Address
Room 202, Guangzhou, 510000, China
×
![Enlarged Chart]()
Oscillators
Invalid data format
Summary
Invalid data format
Moving Averages
Invalid data format
Error: Invalid Earnings JSON format.
Earnings estimate
| Number of analysts | — | — | — | — |
|---|---|---|---|---|
| Average estimate | — | — | — | — |
| Low estimate | — | — | — | — |
| High estimate | — | — | — | — |
| Last year EPS | — | — | — | — |
[stock_revenue_estimate]
Growth estimates
Current qtr
—
Next qtr.
—
Current year
—
Next year
—
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | |
|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total reported revenue | 31.46M | 35.09M | 27.72M |
| Cost of revenue | 4.23M | 7.05M | 4.54M |
| Gross profit | 27.23M | 28.04M | 23.18M |
| Operating expense | |||
| Research & development | 4.27M | 3.86M | 1.04M |
| Selling general and admin | 11.09M | 10.55M | 10.22M |
| Other operating expenses | -791,959 | -1.38M | -1.18M |
| Operating income | 12.65M | 15.01M | 13.09M |
| Non operating interest income | |||
| Income | 1,562 | 8,553 | 2,326 |
| Expense | 285,833 | 299,269 | 153,921 |
| Other income expense | -10,211 | -194,580 | -335,075 |
| Pretax income | 12.36M | 14.52M | 12.61M |
| Tax provision | 1.70M | 1.75M | 2.42M |
| Net income | 10.66M | 12.77M | 10.18M |
| Basic EPS | — | 0.50 | 0.40 |
| Diluted EPS | — | 0.50 | 0.40 |
| Basic average shares | — | 25.15M | 25.15M |
| Diluted average shares | — | 25.15M | 25.15M |
| EBITDA | 14.03M | 16.29M | 14.16M |
| Net income from continuing op. | 10.66M | 12.77M | 10.18M |
| Minority interests | -112,205 | -206,221 | -93,965 |
| Preferred stock dividends | — | — | — |
Balance sheet
| 2023 | 2022 | 2021 | |
|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 56.71M | 42.62M | 25.28M |
| Current assets | |||
| Cash | 1.51M | 1.71M | 3.03M |
| Cash equivalents | — | — | — |
| Cash and cash equivalents | 1.51M | 1.71M | 3.03M |
| Other short term investments | — | — | — |
| Accounts receivable | 31.10M | 24.37M | 11.17M |
| Other receivables | — | — | — |
| Inventory | 1.14M | 1.29M | 3.06M |
| Prepaid assets | 5.81M | 5.80M | 3.25M |
| Restricted cash | — | — | — |
| Assets held for sale | — | — | — |
| Hedging assets | — | — | — |
| Other current assets | 120,485 | 196,999 | 304,293 |
| Non current assets | |||
| Properties | 1.20M | 1.62M | 1.32M |
| Land and improvements | — | — | — |
| Machinery furniture equipment | 4.72M | 1.16M | 1.19M |
| Construction in progress | — | — | — |
| Leases | 4.66M | 2.61M | 2.82M |
| Accumulated depreciation | -3.58M | -2.66M | -2.01M |
| Goodwill | 144,229 | 171,761 | 195,114 |
| Investment properties | — | — | — |
| Financial assets | — | — | — |
| Intangible assets | 25,479 | 49,481 | 62,768 |
| Investments and advances | — | — | — |
| Other non current assets | 1.84M | 252,167 | 159,917 |
| Total liabilities | 21.00M | 16.84M | 10.26M |
| Current liabilities | |||
| Accounts payable | 550,188 | 215,863 | 340,212 |
| Accrued expenses | 864,687 | 104,948 | 158,041 |
| Short term debt | 9.49M | 6.62M | 2.44M |
| Deferred revenue | 593,294 | 712,832 | 731,435 |
| Tax payable | 770,953 | 1.80M | 739,403 |
| Pensions | — | — | — |
| Other current liabilities | — | — | — |
| Non current liabilities | |||
| Long term debt | 2.03M | 816,878 | 494,122 |
| Provision for risks and charges | — | — | — |
| Deferred liabilities | — | — | — |
| Derivative product liabilities | — | — | — |
| Other non current liabilities | — | — | — |
| Shareholders equity | |||
| Common stock | 2,941 | 2,941 | 1 |
| Retained earnings | 14.39M | 3.96M | -6.78M |
| Other shareholders equity | 2.50M | 3.12M | 3.31M |
| Total shareholders equity | 35.71M | 25.78M | 15.02M |
| Additional paid in capital | 18.85M | 18.85M | 18.85M |
| Treasury stock | — | — | — |
| Minority interest | -43,389 | -155,594 | -353,407 |
Cash flow statement
| 2023 | 2022 | 2021 | |
|---|---|---|---|
| Operating Activities | |||
| Net Income | 10.66M | 12.77M | 10.18M |
| Depreciation | 1.38M | 1.47M | 1.40M |
| Deferred Taxes | -541,987 | -143,317 | -45,382 |
| Stock-Based Compensation | — | — | — |
| Other Non-Cash Items | — | — | — |
| Accounts Receivable | -9.67M | -14.10M | -3.49M |
| Accounts Payable | 341,525 | -100,934 | 274,312 |
| Other Assets & Liabilities | -322,147 | 1.12M | -3.18M |
| Operating Cash Flow | 1.84M | 1.02M | 5.14M |
| Investing Activities | |||
| Capital Expenditures | -2.64M | -5.88M | -1.39M |
| Net Intangibles | — | -44,821 | — |
| Net Acquisitions | — | — | — |
| Purchase of Investments | — | — | — |
| Sale of Investments | — | — | — |
| Investing Cash Flow | -2.64M | -5.88M | -1.39M |
| Financing Activities | |||
| Long-Term Debt Issuance | 2.55M | — | — |
| Long-Term Debt Payments | -7.68M | -4.61M | -3.65M |
| Other Financing Charges | -1.01M | -46,397 | 3.59M |
| Financing Cash Flow | -4.02M | -195,007 | -4.87M |
| Other Cash Details | |||
| End Cash Position | 1.51M | 1.71M | 3.03M |
| Income Tax Paid | 2.64M | 1.44M | 3.91M |
| Interest Paid | 261,323 | 243,838 | 90,077 |
| Free Cash Flow | -3.66M | -5.47M | 3.87M |
Error: Invalid format in Holders JSON file.
Article
Baird Medical Advances MWA Training with Expert-Led Course at Columbia Thyroid Center
NEW YORK , Feb. 10, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a leader in microwave ablation (MWA) technology, remains committed to advancing physician education and recently supported Dr. Hosai Todd-Hesham's participation in a specialized MWA training program at the Columbia Thyroid Center in New York City.
Feb 10, 2025
Article
Baird Medical Showcases Groundbreaking MWA Innovations at NASIT 2025
NEW YORK , Feb. 3, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a leader in microwave ablation (MWA) technology, made a significant impact at the 2025 North American Society for Interventional Thyroidology (NASIT) conference.
Feb 3, 2025
Article
Baird Medical Shines at 2025 Microcap Conference: Driving Growth Through Technological Innovation and Strategic Collaborations
NEW YORK , Jan. 30, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a leader in microwave ablation (MWA) technology, today announced its successful participation in the 2025 Microcap Conference, held at the Borgata Hotel in Atlantic City, New Jersey.
Jan 30, 2025
